The Effect of Competing Direct-to-Consumer Advertising Campaigns on the Use of Drugs for Benign Prostatic Hyperplasia: Time Series Analysis
- 469 Downloads
Direct-to-consumer advertising (DTCA) remains a controversial issue, with concerns that it leads to unnecessary and inappropriate prescribing. Whether DTCA shifts prescribing from first-line (guideline-recommended) therapy to second-line drugs has not been studied.
The purpose of this study was to determine the impact of sequential DTCA campaigns for two drugs used to treat benign prostatic hyperplasia (BPH): one newer agent, dutasteride (Avodart®), and one older first-line agent, tamsulosin (Flomax®).
Interrupted time series analysis was used to assess the impact of each DTCA campaign using data on consumer “response” from Google Trends and dispensed prescriptions from IMS Health.
We analyzed data for the United States from January 2003 to December 2007.
DTCA for dutasteride and tamsulosin commenced on July, 2005 and April, 2006, respectively.
Monthly Internet search volume (scaled from 0 to 100) for the advertised trade name of each drug and monthly U.S. prescription rates per 1,000 population were analyzed.
The dutasteride campaign was associated with an increase in Internet searches for both “Avodart” (level change +31.3 %, 95 % CI: 27.2–35.4) and “Flomax” (level change +8.3 %, 95 % CI: 0.9–15.7), whereas the tamsulosin campaign was associated with increased “Flomax” searches (level change +25.3 %, 95 % CI: 18.7–31.8). The dutasteride campaign was associated with an increase in the prescription of dutasteride (trend = 0.45/month, 95 % CI: 0.33–0.56), but a larger impact was observed with tamsulosin prescriptions (trend = 0.76/month, 95 % CI: 0.02–1.50). Similarly, the tamsulosin campaign was associated with an immediate fourfold increase in the prescribing of tamsulosin (level change +5.76 units, 95 % CI: 1.79–9.72) compared to dutasteride (level change +1.47 units, 95 % CI: 0.79–2.14).
DTCA was associated with the utilization of drugs to treat symptomatic BPH. However, both campaigns were associated with greater increases in the use of the guideline-recommended first-line agent. DTCA campaigns may increase the overall levels of guideline-recommended treatments to a greater extent than the specific advertised agents.
KeywordsHealth policy Advertising as topic Benign prostatic hyperplasia
Benign prostatic hyperplasia
5-alpha reductase inhibitor
Sean Skeldon is supported in part by the CIHR and the Western Regional Training Centre (WRTC) for Health Services Research. Katy Kozhimannil is supported by a grant from the Building Interdisciplinary Research Careers in Women’s Health BIRCWH) program (grant number K12HD055887), with funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the Office of Research on Women’s Health, and the National Institute on Aging, at the National Institutes of Health, administered by the University of Minnesota Deborah E. Powell Center for Women’s Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Sumit Majumdar holds the Endowed Chair in Patient Health Management (Faculties of Medicine & Dentistry and Pharmacy & Pharmaceutical Sciences, University of Alberta) and receives salary support as a Health Scholar of the Alberta Heritage Foundation for Medical Research and Alberta Innovates - Health Solutions. Michael Law reports grants from the Canadian Institutes of Health Research during the conduct of the study, and personal fees from Health Canada outside the submitted work.
The statements, findings, conclusions, views, and opinions contained and expressed herein are based in part on data obtained under license from the following IMS Health Incorporated information service(s): National Prescription Audit™(January 2003–December 2007) and National Sales Perspectives™(January 2003–December 2007) IMS Health Incorporated. The statements, findings, conclusions, views, and opinions are not necessarily those of IMS Health Incorporated or any of its affiliated or subsidiary entities.
Conflict of interest
The authors each declare that they have no conflict of interest.
- 16.AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170(2 Pt 1):530–47.Google Scholar
- 22.Ad$pender™ | Kantar Media [Internet]. [cited 2013 Jul 29]; Available from: http://kantarmediana.com/intelligence/products/adspender
- 23.Fox S. Health Information Online. Washington, D.C.: 2005.Google Scholar
- 24.Fox S. Online Health Search 2006. Washington, D.C.: 2006.Google Scholar
- 25.Nielsen NetRatings Search Engine Ratings - Search Engine Watch [Internet]. [cited 2013 Jul 29]; Available from: http://searchenginewatch.com/article/2067079/Nielsen-NetRatings-Search-Engine-Ratings
- 26.Google Trends [Internet]. [cited 2013 Jul 29]; Available from: http://www.google.com/trends/explore#cmpt=q
- 27.IMS National Prescription Audit™, January 2003–December 2007, IMS Health Incorporated.Google Scholar
- 31.U.S. Census Bureau DID. Population Estimates [Internet]. [cited 2013 Jul 29]; Available from: http://www.census.gov/popest/data/intercensal/national/nat2010.html